Genetic medicine is going from strength to strength. But treatment is costly. Luxturna is just the latest flashpoint in the debate over how to afford an innovative medicine.
Every week, we select ten of the most relevant and well-written stories from the global health innovation industry. Here are this week’s can’t-miss articles, including some worrisome news for CRISPR gene editing, some revolutionary treatments out of China, new breakthroughs in CAR-T therapy, and more.
For many years, the long-term success rates for those who attempt to lose excess body weight have hovered around 5-10 percent. In what other disease condition would we accept these numbers and continue on with the same approach?
The number of Nordic exhibitors at Medica has been growing year by year, reaching almost 200 companies in 2017. This is the first time that the Nordics teamed up, organizing a joint networking reception that could be the start to even closer collaboration in the coming years.
Gene therapies captivated the world’s scientists and nonscientists in 2017. There were many good reasons for it, too. These non-invasive gene therapies make changes to the patient’s DNA, the hereditary code that makes us who we are — and which is sometimes responsible for diseases with no known cures. Here are some of the breakthroughs of 2017.
The worst thing most people face at Christmas is often a bit of digestive discomfort from overeating. But for a few unfortunate individuals, Christmas is like a scene from National Lampoon’s Christmas Vacation. To avoid having a Christmas like the Griswolds’, try and learn some lessons from these unfortunate folk.
The Centre for Connected Care (C3) aims to succeed in accelerating adoption and diffusion of patient-centric innovations, i.e. innovations that change patient pathways and delivery systems and increases growth in the healthcare industry. The themes are patient-centric healthcare delivery, innovative infrastructure and interoperability and commercialization, diffusion and adoption
Angel Challenge Health is a workshop based program for Startup Investors and Health Startups. During 8 evening sessions, 20 angel investors work closely together analyzing 20 investor-ready startups that are competing for an investment of 1 million NOK, whilst learning the mechanics and possibilities of investing in the health sector.
INNOLABS aims at fostering collaboration, transfer of knowledge and opportunities among SMEs from different countries and sectors to develop, improve and deliver disruptive technologies on mHealth, personalized healthcare and ageing populations.